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Background
Majeed syndrome is a rare, syndromic form of chronic
recurrent multifocal osteomyelitis (CRMO) first described
in 1989. The syndrome starts during infancy with recur-
rent relapses of osteomyelitis typically associated with
fever, congenital dyserythropoietic anemia (CDA) and
often neutrophilic dermatosis (Sweet syndrome). Homozy-
gous mutations in the LPIN2 gene located on the short
arm of chromosome 18 have been identified as being
responsible for the Majeed syndrome.
Aim
To report a novel mutation in the LPIN2 gene detected
in two brothers with Majeed syndrome and to describe
the clinical characteristics and response to treatment.
Case presentations
Two Turkish brothers (13 (Y) and 29 (M) months old)
with consanguinity of the parents were admitted with
relapsing episodes of pain and ‘pseudoparalysis’ of upper
and lower extremities since the age of 3 and 6 months,
respectively. No concomitant fever has occurred during
the attacks. Whole body MRI of the elder brother (M)
revealed osteomyelitic changes of the metaphyses of
tibiae, left fibula and left radius. Biopsy from lesions
showed no malignancy and negative bacterial cultures.
Both showed significant hypersedimentation (ESR 92
mm/hr (Y) and 96 mm/hr (M)), slight thrombocytosis,
and moderate anemia (Hb 9.0 (Y) and 9.7 (M) g/dl).
Bone marrow aspiration was consistent with congenital
dyserythropoietic anemia (CDA) with 6% - 9% bi- or
multinucleated erythrocytes. LPIN2 gene re-sequencing
of each affected child revealed a homozygous 2 bp dele-
tion (c.1312_1313delCT) resulting in an early truncation
of the protein (L438fs+16X), which confirmed the diag-
nosis in both patients. Clinically, both were refractory to
the treatment with corticosteroids and TNFa inhibition
(etanercept). Elevated plasma levels of proinflammatory
cytokines (IL-1b,I L - 6 ,I L - 8 ,T N F a) did not change sig-
nificantly during the treatment. In M, rapid clinical and
laboratory improvement was observed after introduction
with anakinra (1.7 mg/kg/d), which has not yet been
introduced to Y.
Conclusion
We describe a novel mutation of the LPIN2 gene in two
Turkish brothers with Majeed syndrome. Although our
patients also presented with CDA none of them had
fever during the attacks nor dermatological changes
unlike previously described patients with Majeed. IL-1
inhibition showed promising clinical and laboratory
results.
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